Logo image of MBRX

MOLECULIN BIOTECH INC (MBRX) Stock Fundamental Analysis

NASDAQ:MBRX - Nasdaq - US60855D3098 - Common Stock - Currency: USD

0.42  -0.09 (-17.24%)

Premarket: 0.43 +0.01 (+2.38%)

Fundamental Rating

2

Taking everything into account, MBRX scores 2 out of 10 in our fundamental rating. MBRX was compared to 572 industry peers in the Biotechnology industry. The financial health of MBRX is average, but there are quite some concerns on its profitability. MBRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year MBRX has reported negative net income.
In the past year MBRX has reported a negative cash flow from operations.
In the past 5 years MBRX always reported negative net income.
MBRX had a negative operating cash flow in each of the past 5 years.
MBRX Yearly Net Income VS EBIT VS OCF VS FCFMBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

MBRX's Return On Assets of -128.88% is on the low side compared to the rest of the industry. MBRX is outperformed by 81.59% of its industry peers.
MBRX has a Return On Equity of -403.13%. This is in the lower half of the industry: MBRX underperforms 77.70% of its industry peers.
Industry RankSector Rank
ROA -128.88%
ROE -403.13%
ROIC N/A
ROA(3y)-49.11%
ROA(5y)-51.89%
ROE(3y)-63.3%
ROE(5y)-74.49%
ROIC(3y)N/A
ROIC(5y)N/A
MBRX Yearly ROA, ROE, ROICMBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

MBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBRX Yearly Profit, Operating, Gross MarginsMBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

5

2. Health

2.1 Basic Checks

The number of shares outstanding for MBRX has been increased compared to 1 year ago.
MBRX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MBRX Yearly Shares OutstandingMBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
MBRX Yearly Total Debt VS Total AssetsMBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -12.79, we must say that MBRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.79, MBRX is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
MBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.79
ROIC/WACCN/A
WACCN/A
MBRX Yearly LT Debt VS Equity VS FCFMBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

MBRX has a Current Ratio of 2.08. This indicates that MBRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.08, MBRX is doing worse than 75.58% of the companies in the same industry.
MBRX has a Quick Ratio of 2.08. This indicates that MBRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.08, MBRX is doing worse than 74.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 2.08
MBRX Yearly Current Assets VS Current LiabilitesMBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.15% over the past year.
EPS 1Y (TTM)14.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MBRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.38% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.8%
EPS Next 2Y31.53%
EPS Next 3Y20.22%
EPS Next 5Y11.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBRX Yearly Revenue VS EstimatesMBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
MBRX Yearly EPS VS EstimatesMBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 -20 -30 -40

1

4. Valuation

4.1 Price/Earnings Ratio

MBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBRX Price Earnings VS Forward Price EarningsMBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBRX Per share dataMBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

MBRX's earnings are expected to grow with 20.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.53%
EPS Next 3Y20.22%

0

5. Dividend

5.1 Amount

No dividends for MBRX!.
Industry RankSector Rank
Dividend Yield N/A

MOLECULIN BIOTECH INC

NASDAQ:MBRX (2/12/2025, 8:25:49 PM)

Premarket: 0.43 +0.01 (+2.38%)

0.42

-0.09 (-17.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)N/A N/A
Inst Owners11.06%
Inst Owner Change-79.5%
Ins Owners2.72%
Ins Owner Change0%
Market Cap1.26M
Analysts82.5
Price Target18.36 (4271.43%)
Short Float %5.86%
Short Ratio3.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.54%
Min EPS beat(2)-14.51%
Max EPS beat(2)33.6%
EPS beat(4)2
Avg EPS beat(4)0.4%
Min EPS beat(4)-61.37%
Max EPS beat(4)43.9%
EPS beat(8)5
Avg EPS beat(8)8.38%
EPS beat(12)7
Avg EPS beat(12)9.27%
EPS beat(16)11
Avg EPS beat(16)14.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-43.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.59
EYN/A
EPS(NY)-4.07
Fwd EYN/A
FCF(TTM)-8.09
FCFYN/A
OCF(TTM)-8.06
OCFYN/A
SpS0
BVpS2.49
TBVpS-1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.88%
ROE -403.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.11%
ROA(5y)-51.89%
ROE(3y)-63.3%
ROE(5y)-74.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 2.08
Altman-Z -12.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.59%
Cap/Depr(5y)74.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y48.8%
EPS Next 2Y31.53%
EPS Next 3Y20.22%
EPS Next 5Y11.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.41%
EBIT Next 3YN/A
EBIT Next 5Y10.17%
FCF growth 1Y1.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.85%
OCF growth 3YN/A
OCF growth 5YN/A